We’re very excited to announce that 2016 marks the 25th birthday of our not-for-profit parent body, the Australasian Gastro-Intestinal Trials Group (AGITG).
Over the past 25 years, thanks to your generous donations and through the tireless efforts of the medical professionals at the AGITG, we have achieved significant changes in medical practice not only in Australia, but worldwide.
Since the group was first formed in 1991, we have conducted 48 clinical trials and have involved over 4,000 patients treated at 90 sites in Australia and eight sites in New Zealand.
The work of the AGITG has enabled patients throughout Australia and New Zealand, in regional, rural and city based medical centres to access clinical trials, new personalised treatment options, unfunded cancer treatments and state of the art cancer treatments 3- 5 years earlier than if the research were to be conducted overseas.
Research from the AGITG has improved the life expectancy, treatment and quality of life for patients with gastro-intestinal cancers. This includes playing an important part in intergroup research which has changed international treatment practice for colorectal, GIST and oesophageal cancer patients.
This research contributed to the identification of genetic mutations in colorectal cancer (NCIC-CTG CO.17), provided access to new drugs to determine an improved treatment regimen for GIST (EORTC 62005 and EORTC 62024) and added chemotherapy and radiation therapy before surgery for oesophageal cancer (AGITG meta-analysis).
In the Australasian medical community the AGITG has made significant contributions through the mentoring of oncologists in clinical research, the development of international research links and meaningful consumer (patient, survivor & carer) involvement in concept identification and protocol development.
During 2016 we will reflect upon our 25 year history and we’re looking forward to sharing more of our achievements and plans for the future with you.